Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
181 hedge funds and large institutions have $1.83B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2017 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 65 increasing their positions, 59 reducing their positions, and 37 closing their positions.
159% more call options, than puts
Call options by funds: $33.5M | Put options by funds: $12.9M
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
12% more capital invested
Capital invested by funds: $1.63B → $1.83B (+$200M)
10% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 59
5% less funds holding
Funds holding: 190 → 181 (-9)
19% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair Investment Management
Chicago,
Illinois
|
+$74.8M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$44.7M |
| 3 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$35.1M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$29.8M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$21.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$29.6M |
| 2 |
DM
Deerfield Management
New York
|
-$26.5M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$20.6M |
| 4 |
Goldman Sachs
New York
|
-$15.9M |
| 5 |
Citigroup
New York
|
-$15.7M |
HZNP Hedge Fund Activity: Q3 2017 in Review
181 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q3 2017, worth a combined $1.83B — up 12% from $1.63B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of HZNP and 30 opened new positions — a net loss of 7 holders — while 59 trimmed existing stakes and 65 added.
The largest buyer was William Blair Investment Management, adding an estimated $74.8M. The largest seller was Citadel Advisors, cutting an estimated $29.6M.
- 181 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q3 2017, down from 190 in Q2 2017.
- Funds reported $1.83B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q3 2017, up 12% quarter-over-quarter.
- 30 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q3 2017 and 37 closed out, a net change of -7 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q3 2017 was William Blair Investment Management, an estimated $74.8M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q3 2017 was Citadel Advisors, an estimated $29.6M sold.
Based on aggregated 13F filings for Q3 2017.